%0 Journal Article
%T Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
%A Perrone F
%A Mazzaschi G
%A Minari R
%A Verzè M
%A Azzoni C
%A Bottarelli L
%A Nizzoli R
%A Pluchino M
%A Altimari A
%A Gruppioni E
%A Sperandi F
%A Andrini E
%A Guaitoli G
%A Bertolini F
%A Barbieri F
%A Bettelli S
%A Longo L
%A Pagano M
%A Bonelli C
%A Tagliavini E
%A Nicoli D
%A Ubiali A
%A Zangrandi A
%A Trubini S
%A Proietto M
%A Gnetti L
%A Tiseo M
%J Cancers (Basel)
%V 14
%N 8
%D Apr 2022 16
%M 35454926
%F 6.575
%R 10.3390/cancers14082019
%X <B>BACKGROUND: </B>BRAF mutation involved 2-4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations.<BR><B>METHODS: </B>The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients.<BR><B>RESULTS: </B>A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype.<BR><B>CONCLUSIONS: </B>Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.